BeOne Medicines Ltd. (ONC) shareholders
Close on Nov 16, 2026Market cap $46.76BP/E 73.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Felix J. Baker Joint filing with Julian C. Baker (8.00%), Baker Bros. Advisors LP (8.00%) and 1 more | 115,918,313 | 8.00% | 13D (active) amendment | Apr 16, 2026 |
| Julian C. Baker Joint filing with Felix J. Baker (7.80%), Baker Bros. Advisors LP (7.80%) and 1 more | 115,912,814 | 7.80% | 13D (active) amendment | Sep 14, 2026 |
| HHLR Advisors, Ltd. Joint filing with Hillhouse Investment Management, Ltd. (6.70%) | 92,805,741 | 6.70% | 13D (active) amendment | Mar 3, 2025 |
| John V. Oyler | 71,464,808 | 5.20% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ONC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 8,801,567 | – | $2.51B | +2,514 | 12.57% |
| Primecap Management Co/Ca/ | 5,007,931 | – | $1.43B | +32,750 | 0.84% |
| Capital International Investors | 4,210,221 | – | $1.20B | +51,495 | 0.25% |
| FMR LLC | 2,478,527 | – | $706.31M | −1,215,083 | 0.03% |
| Capital World Investors | 2,249,582 | – | $641.06M | +626,895 | 0.08% |
| Citadel Advisors LLC | 1,425,517 | – | $406.23M | +375,281 | 0.05% |
| Temasek Holdings (Private) Ltd | 845,729 | – | $241.01M | −16,914 | 0.65% |
| Price T Rowe Associates Inc /Md/ | 758,752 | – | $216.22M | +218,983 | 0.02% |
| BlackRock, Inc. | 694,618 | – | $197.95M | +34,117 | 0.00% |
| Millennium Management LLC | 543,323 | – | $154.83M | +338,477 | 0.06% |
| Morgan Stanley | 497,437 | – | $141.75M | +4,978 | 0.01% |
| Siren, L.L.C. | 465,000 | – | $132.51M | – | 2.68% |
| Bank Of America Corp /De/ | 439,336 | – | $125.20M | +34,063 | 0.01% |
| Baird Financial Group, Inc. | 368,978 | – | $105.15M | +19,327 | 0.14% |
| Man Group plc | 307,463 | – | $87.62M | +65,541 | 0.14% |
| Capital International, Inc./CA/ | 305,477 | – | $87.05M | +3,234 | 0.61% |
| Candriam S.C.A. | 289,735 | – | $82.49M | +30,004 | 0.37% |
| Two Sigma Investments, LP | 286,552 | – | $81.66M | +253,009 | 0.06% |
| UBS Group AG | 258,589 | – | $73.69M | −207,300 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 249,758 | – | $71.17M | +139,172 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 283 | 35M | 46 / 110 | 84 / 63 | 3M | 6M |
| Q1 2026 | 307 | 38M | 42 / 117 | 88 / 49 | 6M | 4M |
| Q4 2025 | 318 | 37M | 67 / 117 | 75 / 36 | 2M | 2M |
| Q3 2025 | 292 | 36M | 60 / 102 | 80 / 42 | 3M | 3M |
| Q2 2025 | 274 | 36M | 31 / 96 | 89 / 53 | 1M | 9M |
| Q1 2025 | 297 | 44M | 71 / 99 | 79 / 26 | 6M | 7M |
| Q4 2024 | 256 | 45M | 40 / 88 | 80 / 33 | 3M | 6M |
| Q3 2024 | 252 | 48M | 57 / 53 | 96 / 26 | 4M | 3M |
| Q2 2024 | 223 | 48M | 23 / 77 | 71 / 23 | 1M | 2M |
| Q1 2024 | 225 | 49M | 42 / 97 | 46 / 43 | 4M | 5M |
| Q4 2023 | 229 | 51M | 48 / 58 | 76 / 29 | 2M | 5M |
| Q3 2023 | 215 | 54M | 21 / 75 | 67 / 30 | 7M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
120 funds held ONC in Q2 2026, 8% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ONC | Value | % of fund | As of |
|---|---|---|---|---|---|
| New Perspective Fund | 2,663,960 | – | $759.15M | 0.45% | Jun 30, 2026 |
| Vanguard Primecap Fund | 2,347,622 | – | $669.00M | 0.70% | Jun 30, 2026 |
| Vanguard Capital Opportunity Fund | 1,182,071 | – | $336.85M | 1.03% | Jun 30, 2026 |
| EUPAC Fund | 700,821 | – | $199.71M | 0.14% | Jun 30, 2026 |
| New World Fund Inc | 677,287 | – | $214.03M | 0.24% | Jul 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 646,087 | – | $204.17M | 2.76% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 624,896 | – | $179.92M | 0.18% | May 31, 2026 |
| PRIMECAP Odyssey Growth Fund | 585,087 | – | $184.89M | 3.05% | Jul 31, 2026 |
| iShares Biotechnology ETF | 564,180 | – | $160.77M | 1.77% | Jun 30, 2026 |
| New Economy Fund | 399,178 | – | $114.93M | 0.22% | May 31, 2026 |
| American Funds Global Insight Fund | 374,007 | – | $118.19M | 0.55% | Jul 31, 2026 |
| T. Rowe Price International Stock Fund | 261,437 | – | $82.62M | 0.62% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 245,095 | – | $69.84M | 2.48% | Jun 30, 2026 |
| Baird Chautauqua International Growth Fund | 179,205 | – | $51.07M | 3.91% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 174,859 | – | $50.35M | 0.18% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| John Oyler | Chief Executive Officer, Director | 7,815,448 | Aug 12, 2026 |
| Titus B. Ball | Principal Accounting Officer | 0 | Nov 10, 2026 |
| Chan Henry Lee | SVP, General Counsel | 0 | Nov 9, 2026 |
| Xiaobin Wu | President and COO | 4,000 | Aug 27, 2026 |
| Aaron Rosenberg | Chief Financial Officer | 0 | Aug 5, 2026 |
| Lai Wang | President, Global Head of R&D | 601,965 | Jun 25, 2026 |
| Xiaodong Wang | Director | 4,586,980 | Nov 12, 2026 |
| Bros. Advisors Lp Baker | Director | 922,957 | Sep 16, 2026 |
| Brothers Life Sciences LP Baker | Director | 8,229,958 | Sep 16, 2026 |
| Felix Baker | Director | 997,946 | Sep 16, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 730,643 | Sep 16, 2026 |
| 667, L.P. | Director | 10,803,789 | Sep 16, 2026 |
| Julian Baker | Director | 10,734,144 | Sep 16, 2026 |
| Elizabeth Fisher Mooney | Director | 18,980 | Jun 15, 2026 |
| Margaret Dugan | Director | 73,164 | Jun 15, 2026 |
| Anthony C. Hooper | Director | 83,720 | Jun 15, 2026 |
| Shalini Sharp | Director | 38,116 | Jun 15, 2026 |
| Olivier Brandicourt | Director | 46,306 | Jun 15, 2026 |
| Alessandro Riva | Director | 73,164 | Jun 15, 2026 |
| Charles Lazelle Sawyers | Director | 1,946 | Jun 15, 2026 |
| Qingqing Yi | Director | 0 | Jun 3, 2026 |
| Corazon (Corsee) D. Sanders | Director | 0 | May 27, 2026 |
| Hillhouse Investment Management, Ltd. | 10% owner | 125,045,741 | Dec 4, 2024 |
| Hhlr Advisors, Ltd. | 10% owner | 142,888,241 | Dec 4, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Xiaodong Wang Director | Nov 9, 2026 | Gift | −1,183 | – | – | 4,586,930 |
| Titus B. Ball Principal Accounting Officer | Nov 6, 2026 | Sale | −26 | $406.34 | $10.56K | 0 |
| Titus B. Ball Principal Accounting Officer | Nov 6, 2026 | Sale | −1,533 | $405.55 | $621.71K | 26 |
| Titus B. Ball Principal Accounting Officer | Nov 6, 2026 | Option exercise | +679 | $159.03 | $107.98K | 1,559 |
| Titus B. Ball Principal Accounting Officer | Nov 6, 2026 | Option exercise | +880 | $207.55 | $182.64K | 880 |
| Chan Henry Lee SVP, General Counsel | Nov 5, 2026 | Sale(10b5-1 plan) | −455 | $402.00 | $182.91K | 0 |
| Chan Henry Lee SVP, General Counsel | Nov 5, 2026 | Sale(10b5-1 plan) | −660 | $400.00 | $264.00K | 455 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −6,903 | $366.22 | $2.53M | 0 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −3,965 | $365.43 | $1.45M | 6,903 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −2,841 | $363.95 | $1.03M | 10,868 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −8,148 | $363.24 | $2.96M | 13,709 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −2,331 | $362.35 | $844.64K | 21,857 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −320 | $360.64 | $115.40K | 24,188 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −1,280 | $359.72 | $460.44K | 24,508 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −1,681 | $358.75 | $603.05K | 25,788 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −1,239 | $357.54 | $442.99K | 27,469 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −1,440 | $355.62 | $512.09K | 28,708 |
| Xiaodong Wang Director | Oct 27, 2026 | Sale(10b5-1 plan) | −880 | $355.56 | $312.89K | 30,148 |
| Xiaodong Wang Director | Oct 27, 2026 | Option exercise | +31,028 | $36.90 | $1.14M | 31,028 |
| Xiaodong Wang Director | Oct 13, 2026 | Sale(10b5-1 plan) | −1,260 | $353.24 | $445.08K | 0 |
| Xiaodong Wang Director | Oct 13, 2026 | Sale(10b5-1 plan) | −6,558 | $352.57 | $2.31M | 1,260 |
| Xiaodong Wang Director | Oct 13, 2026 | Sale(10b5-1 plan) | −5,681 | $351.40 | $2.00M | 7,818 |
| Xiaodong Wang Director | Oct 13, 2026 | Sale(10b5-1 plan) | −10,361 | $350.47 | $3.63M | 13,499 |
| Xiaodong Wang Director | Oct 13, 2026 | Sale(10b5-1 plan) | −7,167 | $349.56 | $2.51M | 23,860 |
| Xiaodong Wang Director | Oct 13, 2026 | Option exercise | +31,027 | $36.90 | $1.14M | 31,027 |
| Chan Henry Lee SVP, General Counsel | Sep 30, 2026 | Sale(10b5-1 plan) | −1,115 | $375.00 | $418.13K | 0 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −4,239 | $362.17 | $1.54M | 24,228 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −14,525 | $366.58 | $5.32M | 738 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −2,047 | $365.85 | $748.89K | 15,263 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −3,419 | $364.07 | $1.24M | 17,310 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −3,499 | $363.10 | $1.27M | 20,729 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −738 | $367.23 | $271.02K | 0 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −2,241 | $361.05 | $809.11K | 28,467 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −40 | $359.16 | $14.37K | 30,708 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −120 | $358.71 | $43.05K | 30,748 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −160 | $356.97 | $57.12K | 30,868 |
| Xiaodong Wang Director | Sep 28, 2026 | Option exercise | +31,028 | $36.90 | $1.14M | 31,028 |
| Bros. Advisors Lp Baker Director | Sep 14, 2026 | Option exercise | +30,768 | $36.83 | $1.13M | 761,410 |
| Bros. Advisors Lp Baker Director | Sep 14, 2026 | Option exercise | +30,768 | $36.83 | $1.13M | 8,099,179 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,278 | $351.25 | $2.21M | 0 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,841 | $346.16 | $983.44K | 3,238 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,517 | $347.39 | $526.99K | 1,721 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,721 | $348.01 | $598.93K | 0 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,569 | $350.27 | $2.30M | 6,278 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,181 | $345.38 | $407.89K | 6,079 |
| Xiaodong Wang Director | Sep 8, 2026 | Option exercise | +31,027 | $36.90 | $1.14M | 31,027 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −7,492 | $348.31 | $2.61M | 23,535 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −10,688 | $349.28 | $3.73M | 12,847 |
| Titus B. Ball Principal Accounting Officer | Sep 1, 2026 | Sale | −132 | $355.86 | $46.97K | 0 |
| Xiaobin Wu President and COO | Aug 25, 2026 | Sale(10b5-1 plan) | −280 | $380.00 | $106.40K | 0 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −20,899 | $358.41 | $7.49M | 14,102 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −15,396 | $357.63 | $5.51M | 35,001 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −2,515 | $356.43 | $896.42K | 50,397 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −1,980 | $354.71 | $702.33K | 52,912 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −14,102 | $359.12 | $5.06M | 0 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +812 | $194.47 | $157.91K | 812 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +1,058 | $213.32 | $225.69K | 1,870 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +796 | $159.03 | $126.59K | 2,666 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Sale(10b5-1 plan) | −2,666 | $360.00 | $959.76K | 0 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −4 | $367.00 | $1.47K | 54,892 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of BeOne Medicines's stock actually held short. Settlement fails (shares not delivered on time) peaked at 27,633 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Titus B. Ball Officer | Nov 6, 2026 | 1,559 | $632.28K | Nov 6, 2026 | Exercise of Options Under a Registered Plan |
| Chan Henry Lee Officer | Nov 5, 2026 | 1,115 | $421.22K | Nov 5, 2026 | Restricted Stock Units |
| Chan Henry Lee Officer | Sep 30, 2026 | 1,115 | $407.28K | Sep 30, 2026 | Restricted Stock Units |
| Xiaodong Wang Director, Chair, Scientific Advisory Brd | Sep 8, 2026 | 131,370 | $47.06M | Sep 8, 2026 | Exercise of Stock Options |
| Titus B. Ball Officer | Sep 1, 2026 | 132 | $46.97K | Sep 1, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Corazon (Corsee) D. Sanders Former Director | Aug 25, 2026 | 2,075 | $788.50K | Aug 25, 2026 | Exercise of Options Under a Registered Plan |
| Xiaobin Wu Officer | Aug 25, 2026 | 15,000 | $5.58M | Aug 25, 2026 | Restricted Stock Units |
| Chan Henry Lee Officer | Aug 11, 2026 | 2,002 | $718.72K | Aug 11, 2026 | Exercise of Stock Options |
| John Oyler Director, Officer | Aug 10, 2026 | 240,810 | $83.87M | Aug 10, 2026 | Previously Exercised Stock Options |
| Aaron Rosenberg Officer | Aug 3, 2026 | 1,157 | $361.81K | Aug 3, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Chan Henry Lee Officer | Jul 30, 2026 | 1,044 | $337.93K | Jul 30, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Chan Henry Lee Officer | Jul 22, 2026 | 2,001 | $637.69K | Jul 22, 2026 | Exercise of Stock Options |
| John Oyler Director, Officer | Jul 14, 2026 | 513,574 | $156.11M | Jul 14, 2026 | Exercise of Stock Options |
| Pan-Oyler Foundation Director, Officer | Jul 10, 2026 | 49,541 | $15.00M | Jul 10, 2026 | Founders Shares |
| John Oyler Director, Officer | Jul 10, 2026 | 150,000 | $45.42M | Jul 10, 2026 | Exercise of Stock Options |
See a number that looks wrong?